Literature DB >> 29850190

Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.

Takehiro Uemura1, Toyoaki Hida1.   

Abstract

Entities:  

Year:  2018        PMID： 29850190      PMCID： PMC5949402          DOI： 10.21037/jtd.2018.03.180

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

Review 3.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Authors:  Monica Khunger; Sagar Rakshit; Vinay Pasupuleti; Adrian V Hernandez; Peter Mazzone; James Stevenson; Nathan A Pennell; Vamsidhar Velcheti
Journal:  Chest       Date:  2017-05-10       Impact factor: 9.410

Review 4.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

5.  Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Matthew Links; Val Gebski; Tony Mok; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-10-17       Impact factor: 15.609

Review 6.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

7.  Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

Authors:  Jin Seok Ahn; Yong Chan Ahn; Joo-Hang Kim; Chang Geol Lee; Eun Kyung Cho; Kyu Chan Lee; Ming Chen; Dong-Wan Kim; Hoon-Kyo Kim; Young Joo Min; Jin-Hyoung Kang; Jin-Hyuck Choi; Sang-We Kim; Guangying Zhu; Yi-Long Wu; Sung Rok Kim; Kyung Hee Lee; Hong Suk Song; Yoon-La Choi; Jong-Mu Sun; Sin-Ho Jung; Myung-Ju Ahn; Keunchil Park
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

10.  DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.

Authors:  Hiro Sato; Atsuko Niimi; Takaaki Yasuhara; Tiara Bunga Mayang Permata; Yoshihiko Hagiwara; Mayu Isono; Endang Nuryadi; Ryota Sekine; Takahiro Oike; Sangeeta Kakoti; Yuya Yoshimoto; Kathryn D Held; Yoshiyuki Suzuki; Koji Kono; Kiyoshi Miyagawa; Takashi Nakano; Atsushi Shibata
Journal:  Nat Commun       Date:  2017-11-24       Impact factor: 14.919
View more
  9 in total

Review 1.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

2.  Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.

Authors:  Julian Taugner; Lukas Käsmann; Chukwuka Eze; Maurice Dantes; Olarn Roengvoraphoj; Kathrin Gennen; Monika Karin; Oleg Petruknov; Amanda Tufman; Claus Belka; Farkhad Manapov
Journal:  Transl Lung Cancer Res       Date:  2019-10

Review 3.  [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].

Authors:  Di Zhang; Jiaqi Huang; Chufeng Zhang; Yan Guan; Qisen Guo
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-06-20

4.  Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo.

Authors:  Zujun Que; Bin Luo; Zhiyi Zhou; Changsheng Dong; Yi Jiang; Lin Wang; Qihui Shi; Jianhui Tian
Journal:  Cancer Cell Int       Date:  2019-01-29       Impact factor: 5.722

5.  Effect of Pretreatment Platelet Parameters on Survival in Limited Disease Small Cell Lung Cancer.

Authors:  Abdullah Sakin; Nurgul Yasar; Serdar Arici; Cumhur Demir; Caglayan Geredeli; Ferdi Aksaray; Selver Isik; Sener Cihan
Journal:  Asian Pac J Cancer Prev       Date:  2019-06-01

Review 6.  Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.

Authors:  Kamila Wojas-Krawczyk; Tomasz Kubiatowski
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

7.  Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.

Authors:  Yuanming Li; Runqi Guo
Journal:  J Oncol       Date:  2022-03-15       Impact factor: 4.375

8.  Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.

Authors:  Joanna Kapeleris; Juliana Müller Bark; Shanon Ranjit; Darryl Irwin; Gunter Hartel; Majid Ebrahimi Warkiani; Paul Leo; Connor O'Leary; Rahul Ladwa; Kenneth O'Byrne; Brett G M Hughes; Chamindie Punyadeera
Journal:  Heliyon       Date:  2022-07-19

9.  Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.

Authors:  Shu-Ling Zhang; Cheng-Bo Han; Li Sun; Le-Tian Huang; Jie-Tao Ma
Journal:  Radiat Oncol       Date:  2020-08-24       Impact factor: 3.481
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.